Kenneth A Bauer
Overview
Explore the profile of Kenneth A Bauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
4470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaudhry S, Haj A, Ryu J, Jurgens S, Rodriguez Espada A, Wang X, et al.
JAMA
. 2025 Mar;
PMID: 40029645
Importance: Clinical decision-making in thrombotic disorders is impeded by long-standing uncertainty regarding the magnitude of venous and arterial thrombosis risk associated with low protein S. Population-scale multiomic datasets offer an...
2.
Chiang C, Song J, Chang Y, Osataphan S, Lee Y, Chang K, et al.
Blood Adv
. 2025 Feb;
PMID: 39908569
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are anti-diabetes agents recently approved for weight loss. Obesity is an established risk factor for venous thromboembolism (VTE). Moreover, preclinical studies have shown that...
3.
Barnum K, Patell R, Berry J, Bauer K
J Thromb Haemost
. 2024 Oct;
23(2):404-416.
PMID: 39442623
Splanchnic vein thrombosis (SpVT) is an uncommon site of venous thrombosis that is associated with complications including portal hypertension and hepatic dysfunction. The evaluation and management of this patient population...
4.
Ryu J, Ramo J, Jurgens S, Niiranen T, Sanna-Cherchi S, Bauer K, et al.
Blood
. 2024 Mar;
143(23):2425-2432.
PMID: 38498041
The factor V Leiden (FVL; rs6025) and prothrombin G20210A (PTGM; rs1799963) polymorphisms are 2 of the most well-studied genetic risk factors for venous thromboembolism (VTE). However, double heterozygosity (DH) for...
5.
Chiasakul T, Bauer K
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):593-599.
PMID: 38066917
Considerable progress has been made in elucidating genetic and biologic risk factors for venous thromboembolism (VTE). Despite being able to identify heritable defects in a substantial proportion of patients with...
6.
Ryu J, Bauer K, Schulman S
J Thromb Haemost
. 2023 Sep;
21(12):3508-3510.
PMID: 37734716
Type 2 Normandy von Willebrand disease (type 2N VWD) is a rare qualitative defect in von Willebrand factor (VWF) that results in impaired factor VIII (FVIII) binding and consequently reduced...
7.
Rezende S, Bauer K, Zakai N
Blood Adv
. 2023 Jun;
7(18):5199-5201.
PMID: 37276085
No abstract available.
8.
Liu J, Elsamadisi P, Philips E, Bauer K, Eche I
Am J Health Syst Pharm
. 2022 Mar;
79(16):1323-1329.
PMID: 35291008
Purpose: To manage factor Xa (FXa) inhibitor-associated bleeding, andexanet alfa or 4-factor prothrombin concentrate (4F-PCC) has been used to restore hemostasis. However, literature on the outcomes for patients who received...
9.
Sharda A, Fatovic K, Bauer K
Res Pract Thromb Haemost
. 2022 Feb;
6(1):e12649.
PMID: 35106432
Background: Aspirin is commonly used as the only pharmacologic agent for prevention of venous thromboembolism (VTE) after joint replacement surgery in the United States. Despite this, prospective studies investigating VTE...
10.
Zhu V, Zhao J, Gao Y, Syn N, Zhang S, Ou S, et al.
Lung Cancer
. 2021 May;
157:147-155.
PMID: 34049720
Introduction: Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). Materials And Methods: Odds ratios (OR) and hazard ratios (HR) of TE were calculated...